Cord blood has fewer matching requirements than bone marrow or peripheral blood transplants, providing the potential to increase the number of suitable transplant matches and to shorten the time it can take to find a match. However, there are a limited number of stem/progenitor cells in each cord blood unit, often limiting unrelated cord blood transplants to younger, smaller pediatric patients. StemEx employs a technology that expands this small number of cord blood stem/progenitor cells, potentially increasing their therapeutic capacity for transplantation in adolescents and adults.
"Our goal is to develop a product that will effectively treat blood cancers like leukemia and lymphoma. It is with this goal in mind that the ExCell team is studying the effects of StemEx. It is our hope that more doctors, patients and the friends and family of patients will become familiar with this study," said David Snyder, vice president of clinical development.
ABOUT THE CHILDREN'S HOSPITAL
The Children's Hospital has defined and delivered pediatric healthcare
excellence for more than 100 years. Founded in 1908, The Children's Hospital
is a leading pediatric network entirely devoted to the health and wellbeing
of children. Continually recognized as one of the nation's outstanding
hospitals by U.S. News & World Report, The Children's Hospital is known both
for its nationally and internationally recognized medical, research and
education programs as well as the full spectrum of everyday care for kids
throughout Colorado and surrounding states. With more than 1,000 healthcare
|SOURCE Gamida Cell LTD|
Copyright©2009 PR Newswire.
All rights reserved